aTYR PHARMA INC (ATYR) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -63.86M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 47.09M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-63.86M | (m) | (m) | $47.09M | (m) | (m) |
| 2026-03-31 | $-73.29M | (m) | (m) | $55.72M | (m) | (m) |
| 2025-12-31 | $-77.63M | $190.00K | (m) | $60.22M | (m) | -40856.32% |
| 2025-09-30 | $-78.65M | $190.00K | (m) | $61.56M | (m) | -41395.26% |
| 2025-06-30 | $-70.05M | $0.00 | (m) | $54.23M | (m) | (m) |
| 2025-03-31 | $-67.05M | $0.00 | (m) | $52.82M | (m) | (m) |
| 2024-12-31 | $-67.91M | $235.00K | (m) | $54.37M | (m) | -28899.57% |
| 2024-09-30 | $-68.05M | $235.00K | (m) | $54.90M | (m) | -28958.72% |
| 2024-06-30 | $-62.52M | $588.00K | (m) | $50.41M | (m) | -10633.50% |
| 2024-03-31 | $-58.77M | $588.00K | (m) | $46.28M | (m) | -9994.56% |
| 2023-12-31 | $-54.92M | $353.00K | (m) | $42.29M | (m) | -15557.79% |
| 2023-09-30 | $-46.91M | $10.74M | (m) | $44.45M | (m) | -436.82% |
| 2023-06-30 | $-47.79M | (m) | (m) | $44.00M | (m) | (m) |
| 2023-03-31 | $-46.81M | (m) | (m) | $43.29M | (m) | (m) |
| 2022-12-31 | $-46.40M | $10.39M | (m) | $42.81M | (m) | -446.79% |
| 2022-09-30 | $-47.09M | (m) | (m) | $33.85M | (m) | (m) |
| 2022-06-30 | $-41.33M | (m) | (m) | $29.12M | (m) | (m) |
| 2022-03-31 | $-39.19M | (m) | (m) | $27.64M | (m) | (m) |
| 2021-12-31 | $-34.02M | (m) | (m) | $23.26M | (m) | (m) |
| 2021-09-30 | $-30.32M | (m) | (m) | $22.01M | (m) | (m) |
| 2021-06-30 | $-29.10M | (m) | (m) | $21.48M | (m) | (m) |
| 2021-03-31 | $-24.97M | (m) | (m) | $18.19M | (m) | (m) |
| 2020-12-31 | $-15.91M | $10.46M | (m) | $17.29M | (m) | -152.19% |
| 2020-09-30 | $-16.93M | $8.55M | (m) | $16.18M | (m) | -198.14% |
| 2020-06-30 | $-15.92M | $8.58M | (m) | $15.37M | (m) | -185.49% |
| 2020-03-31 | $-15.24M | $8.49M | (m) | $14.32M | (m) | -179.59% |
| 2019-12-31 | $-22.98M | $422.00K | (m) | $14.05M | (m) | -5445.02% |
| 2019-09-30 | $-22.98M | (m) | (m) | $14.01M | (m) | (m) |
| 2019-06-30 | $-24.16M | (m) | (m) | $14.41M | (m) | (m) |
| 2019-03-31 | $-28.48M | (m) | (m) | $17.58M | (m) | (m) |
| 2018-12-31 | $-32.82M | (m) | (m) | $20.39M | (m) | (m) |
| 2018-09-30 | $-38.06M | (m) | (m) | $22.15M | (m) | (m) |
| 2018-06-30 | $-42.21M | (m) | (m) | $25.08M | (m) | (m) |
| 2018-03-31 | $-44.15M | (m) | (m) | $27.01M | (m) | (m) |
| 2017-12-31 | $-47.15M | (m) | (m) | $30.07M | (m) | (m) |
| 2017-09-30 | $-48.47M | (m) | (m) | $33.90M | (m) | (m) |
| 2017-06-30 | $-51.51M | (m) | (m) | $37.16M | (m) | (m) |
| 2017-03-31 | $-55.04M | (m) | (m) | $40.05M | (m) | (m) |
| 2016-12-31 | $-57.94M | (m) | (m) | $42.85M | (m) | (m) |
| 2016-09-30 | $-61.90M | (m) | (m) | $46.37M | (m) | (m) |
| 2016-06-30 | $-59.34M | (m) | (m) | $43.72M | (m) | (m) |
| 2016-03-31 | $-54.81M | (m) | (m) | $39.91M | (m) | (m) |
| 2015-12-31 | $-47.62M | (m) | (m) | $34.50M | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-23.55M | (m) | (m) | $16.78M | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-19.54M | (m) | (m) | $13.83M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |